Tetratherix

Tetratherix EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Tetratherix (TTX.AX) as of Oct 26, 2026 is -49.14. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -73.09 — a change of -32.77% (higher).

EV/FCF

-49.14

YoY

-32.77%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Tetratherix is 2025 -49.14 . EV/FCF (Enterprise Value to Free Cash Flow) of Tetratherix was 2024 -73.09 . It decreases by -32.77% higher compared to the previous year.

The Tetratherix EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2023
-481.91 AUD
Jan 1, 2024
-73.09 AUD
Jan 1, 2025
-49.14 AUD
The Tetratherix EV/FCF history
YEAREV/FCFYoY
-49.14-32.77%
-73.09-84.83%
-481.91—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tetratherix Stock analysis

What does Tetratherix do? Tetratherix Ltd. develops a biostealth fluid matrix for regenerative medicine, creating injectable products that form 3D matrices upon physiological temperature exposure. The company's biomaterial platform uses polymer programming for implantable solutions, with Tegenix and TegenEOS serving as carriers mixed with bone graft materials for dental, oral, and orthopedic applications. TetraDerm products address surgical incision sites to minimize scarring, while Tutelix functions as a spacer to mitigate radiation therapy side effects in prostate cancer. The firm's manufacturing center in Sydney handles cleanroom production of these medical solutions. The company's revenue streams come from selling Tegenix, TegenEOS, TetraDerm, and Tutelix products to healthcare providers, hospitals, and medical device distributors specializing in regenerative medicine. These products target clinical segments including dental procedures, orthopedic surgery, and oncology treatments. Tetratherix's injectable fluid matrix technology differentiates its offerings by enabling tissue integration without causing bodily damage during application, supporting its positioning in the regenerative medicine market. Tegenix and TegenEOS are marketed as complementary solutions for bone graft applications, while TetraDerm focuses on post-surgical scar reduction. Tutelix specifically addresses radiation therapy side effects in prostate cancer patients. The company's manufacturing center in Sydney ensures quality production of these medical products, which are distributed to healthcare professionals across dental, orthopedic, and oncology fields. Tetratherix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tetratherix stock

EV/FCF (Enterprise Value to Free Cash Flow) of Tetratherix is -49.14 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Tetratherix changed from -73.09 to -49.14, representing a -32.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Tetratherix since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Tetratherix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Tetratherix

All Key Metrics — Tetratherix